8-K: MetaVia Announces Positive Phase 1 Trial Results for Obesity Drug DA-1726 and Secures $10 Million in Private Placement

MetaVia reports positive Phase 1 trial results for DA-1726, showing compelling weight loss and glucose control, and secures $10 million in a private placement to fund operations into 2026.

Summary

• MetaVia Inc., a clinical-stage biotechnology company, announced its first quarter 2025 financial results and provided a corporate update.
• The company reported positive results from the Phase 1 trial of DA-1726, an obesity treatment, showing significant weight loss and glucose control.
• A private placement was successfully completed, raising $10 million in gross proceeds.
• The company's cash position is expected to fund operations into 2026.
• DA-1241, a MASH treatment, showed liver-protective and glucose-regulating effects in a Phase 2a clinical trial.
• Research and Development expenses decreased to $2.3 million from $4.9 million year-over-year.
• General and Administrative expenses decreased to $1.6 million from $2.0 million year-over-year.
• The net loss for the quarter was $3.7 million, or $0.36 per share, compared to a net loss of $6.7 million, or $1.32 per share, in the same quarter last year.
• Cash was $11.2 million as of March 31, 2025, with an additional $10 million from the private placement.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to promising clinical trial results, successful fundraising, and reduced operating expenses. The company appears to be making significant progress in its drug development programs.

Positives

• DA-1726 demonstrated significant weight loss and glucose control in Phase 1 trials.
• DA-1241 showed liver-protective and glucose-regulating effects in Phase 2a trials.
• The company successfully completed a $10 million private placement.
• Cash runway extends into 2026.
• Research and Development expenses decreased year-over-year.
• General and Administrative expenses decreased year-over-year.
• Net loss decreased year-over-year.

Negatives

• The company reported a net loss of $3.7 million for the quarter.
• Cash decreased from $16.0 million at the end of 2024 to $11.2 million as of March 31, 2025, prior to the private placement.

Risks

• The company's future performance depends on the successful development and regulatory approval of its product candidates.
• Clinical trial results may not be consistent with pre-clinical and previous clinical trials.
• The company's ability to execute its commercial strategy is subject to various risks and uncertainties.
• Changes in applicable laws or regulations could negatively impact the company.
• The company's stock price could affect the terms of the license agreement and any future fundraising.

Future Outlook

The company expects to begin additional SAD/MAD cohorts to explore the maximum tolerated dose of DA-1726 in the third quarter of 2025, with data expected in the fourth quarter of 2025. The company expects to have an end-of-Phase 2 meeting with the FDA regarding DA-1241 in the first half of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of MetaVia, stated that the company achieved significant progress advancing the clinical development of its two next-generation cardiometabolic assets.
• Mr. Kim also mentioned that the company is well capitalized into 2026 after a successful private placement of $10 million in aggregate gross proceeds.
• Mr. Kim continued, 'We look forward to discussing these findings with the FDA in the first half of 2025.'

Industry Context

The announcement highlights MetaVia's progress in the competitive fields of obesity and MASH treatment, where there is a high unmet need for effective and safe therapies. The positive clinical trial results position MetaVia as a potential player in these markets.

Comparison to Industry Standards

• DA-1726's weight loss results are promising compared to existing GLP-1 therapies, with the added benefit of potential glucose control.
• The reported tolerability profile of DA-1726 suggests a potentially superior profile compared to existing GLP-1 therapies.
• DA-1241's liver-protective and glucose-regulating effects are notable in the MASH treatment landscape, where few therapies have demonstrated both benefits.
• Companies like Viking Therapeutics and Madrigal Pharmaceuticals are also developing MASH treatments, and MetaVia's DA-1241 could potentially compete with these therapies.

Related Party Transactions

• Included in direct R&D costs were expenses totaling $1.1 million and $0.2 million for the three months ended March 31, 2025 and 2024, respectively, related to investigational drug manufacturing, non-clinical and preclinical costs incurred under the Shared Services Agreement with Dong-A (related party).

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results and successful fundraising.
• Employees may be encouraged by the company's progress and extended cash runway.
• Patients may benefit from the development of new and effective therapies for obesity and MASH.

Next Steps

• Additional SAD/MAD cohorts to explore the maximum tolerated dose of DA-1726 are expected to begin in the third quarter of 2025, with data expected in the fourth quarter of 2025.
• The company expects to have an end-of-Phase 2 meeting with the FDA regarding DA-1241 in the first half of 2025.

Key Dates

Keywords

MetaVia, DA-1726, DA-1241, Obesity, MASH, Clinical Trial, Private Placement, Biotechnology, Cardiometabolic Diseases, Financial Results